Doximity, Inc.

Valuation Analysis

About the Company

Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; a

Doximity, Inc. Stock at a Glance

Doximity, Inc. (DOCS) is currently trading at $20.04 with a market capitalization of $3.7B. The trailing P/E ratio stands at 20.45x, with a forward P/E of 12.55x. The 52-week range spans from $17.15 to $76.51; the current price is 73.8% below the yearly high. Year-over-year revenue growth stands at +5.1%. The net profit margin stands at 30.4%.

💰 Dividend

Doximity, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

19 analysts rate Doximity, Inc. (DOCS) on consensus: Buy. The average price target is $25.42, implying +26.85% from the current price. Analyst price targets range from $18.00 to $42.00.

Doximity, Inc.: The Investment Case in Detail

Doximity, Inc. (DOCS) operates in the Healthcare — specifically Health Information Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 89.09%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 30.4%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 26.85% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Short interest sits at 12.7% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.59, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 12.55x is meaningfully below the trailing 20.45x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 26.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (12.7%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Doximity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.